UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 4, 2019

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-38418	35-2528215
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

19805 N. Creek Parkway Bothell, WA	98011
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (786)-459-1831

(Former name or former address, if changed since last report.): N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7.01 Regulation FD Disclosure

Beginning on January 7, 2019, senior executives of Cocrystal Pharma, Inc. (the "Company") will hold a series of meetings with the members of the scientific and financial community. A copy of the Company's presentation to be used in connection with these meetings is being furnished as Exhibit 99.1 hereto and is hereby incorporated by reference. The presentation is also available on the Company's website at www.cocrystalpharma.com.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 (the "Securities Act"), or the Exchange Act.

Item 8.01 Other Events

Dr. Phillip Frost, a director and a principal shareholder of the Company has entered into a settlement agreement with the Securities and Exchange Commission (the "SEC"), subject to court approval, to resolve the action brought against him and certain other parties named in the complaint (the "Complaint") filed with the U.S. District Court for the Southern District of New York on September 7, 2018.

Pursuant to the terms of the settlement agreement between the SEC and Dr. Frost, and without admitting or denying any of the allegations in the Complaint, Dr. Frost agreed that he will be enjoined from violating Sections 5(a) and (c) and 17(a)(2) of the Securities Act and Section 13(d) of the Securities Exchange Act; will pay approximately $5.5 million in penalty, disgorgement and pre-judgment interest; and will be prohibited, subject to certain exceptions, from trading in penny stocks. Liability under Section 13(d) of the Exchange Act and Sections 5(a) and (c) of the Securities Act can be established without any showing of wrongful intent or negligence, and liability under Section 17(a)(2) of the Securities Act can be established upon a showing of negligence.

OPKO Health, Inc., a principal shareholder of the Company, of which Dr. Frost is CEO and Chairman, and Frost Gamma Investments Trust, of which Dr. Frost is the trustee, have also entered into a settlement agreements with the SEC to resolve the allegations against them set forth in the Complaint.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit	Description
99.1	Cocrystal Pharma, Inc. Corporate Presentation, dated January 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cocrystal Pharma, Inc.

Date: January 4, 2019

By: */s/ James Martin*
Name: James Martin
Title: Chief Financial Officer


COCRYSTAL
PHARMA, INC.
Antiviral Therapies
Corporate Presentation
January 2019
NASDAQ: COCP
www.cocrystalpharma.com

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated timing of our drug development programs, including milestones, anticipated completion or initiation of studies, expected 2019 growth, including collaboration with Merck, and new leads and opportunities in the influenza antiviral market. Forward-looking statements are prefaced by words such as "expect," "plan," "intend," "anticipate," and similar words. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. We caution you, therefore, against relying on any of these forward-looking statements. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons, including delays in manufacturing created by third parties, the ability of clinical research organizations to recruit patients, and the unanticipated development obstacles with our programs. Also see the risk factors contained in the Prospectus Supplement dated July 19, 2018, and our Annual Report on Form 10-K for the year ended December 31, 2017. Any forward-looking statement made by us in this presentation speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Corporate Overview

Highlights
Clinical Stage Antiviral Company
Proprietary Drug Discovery Platform
Merck Influenza Collaboration

Target Diseases
Influenza
Hepatitis
Norovirus Gastroenteritis

Seasoned Management Team

Gary Wilcox, Ph.D.
Vice Chairman and Chief Executive Officer
Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis

Sam Lee, Ph.D.
President
Over 20 years of anti-infective drug discovery research experience and played a key role in the early development of phosphoinositide 3-kinase (PI3K) delta inhibitors

James J. Martin, MBA, CPA
Chief Financial Officer
25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies

2019: Strong Outlook

- Growth in focused therapeutic areas
- Continue to build an innovative pipeline
- Strategic collaborations and partnerships
- Recent collaboration with Merck will accelerate influenza drug development program

Cocrystal/Merck Team Initiate Influenza Collaboration

- Recently signed a collaboration agreement
- Merck will fund:
  - Research and development
  - Clinical development
  - Worldwide commercialization of any products derived from the collaboration
- Cocrystal will receive an upfront payment (undisclosed) and milestone payments up to $156 M and royalties (undisclosed) on product sales
- Dedicated joint research committee in place

Influenza Death Risk On The Rise in US Despite Vaccines

TIME
@TIME

The flu is killing up to 4,000 Americans a week

The Flu is Killing Up to 4,000 Americans a Week

The amount of influenza ravaging the U.S. rivals levels seen when an altogether new virus emerge

fortune.com

10 Feb 2018

CNN Health » Food | Fitness | Wellness | Parenting | Vital Signs

Live TV | U.S. Edition +

Flu season deaths top 80,000 last year, CDC says

September 27, 2018

AN AAFP BULLETIN INVESTIGATIVE REPORT

FLU DEATHS ON THE RISE FOR OLDER AMERICANS

Fatalities jump sixfold over two years; experts say current vaccines are ineffective at blocking an evolving virus

October 2, 2018

The New York Times

This Flu Season Is the Worst in Nearly a Decade

Jan. 26, 2018

AAP News

June 1, 2018

CDC: Pediatric flu deaths rise to 171, tying record

Melissa Jenco, News Content Editor

Flu deaths in children this season have risen to 171, tying a record for a non-pandemic year, according to the Centers for Disease Control and Prevention (CDC).

"This is a wake-up call for the world"

Michael Osterholm,
Director of the Center for Infectious Disease Research and Policy at the University of Minnesota

October 2, 2018

Great Opportunity in Influenza Antiviral Market

- Seasonal and pandemic infection
  - 3-5 million cases of severe illness per year
  - 250,000 – 500,000 deaths worldwide*
- Approved influenza therapies have major limitation
- Multiple product routes of delivery, inhalation, oral, and intravenous (IV)
- Stock piling and prophylactic market in addition to therapeutic market

*Reference: https://www.cdc.gov/flu/about/disease/burden

Influenza A/B Inhibitor: Cocrystal/Merck Collaboration Program

Proprietary influenza A and B crystals



- Broad spectrum, potent dual influenza A/B preclinical lead will be developed
  - Results of Cocrystal's drug discovery platform technology
  - Binds to highly conserved site of influenza A and B replication complex
  - Active against seasonal, pandemic, and drug-resistant influenza A and B strains
  - Expected to exhibit superior drug resistant profile

Influenza A PB2 Preclinical Lead, CC-42344 Properties



Cocrystal structure of CC-42344 (1.47 Å)

- Binds to the highly conserved m7GTP binding pocket of PB2
- Exhibits broad spectrum activity against seasonal and pandemic influenza strains, EC_{50} 0.12-9 nM
- Favorable preclinical safety profile and pharmacokinetic properties
- Multiple routes of administration (oral, inhalation, and IV) explored

Cocrystal Technology

Based on Nobel Prize Winning Technology



Innovative Drug Discovery Platform Technology Developed



- Fully optimized operations from expression through high resolution X-ray data
- Stringent Quality oversight of procedures for crystal production
- High throughput X-ray data collection and computation methods
- Crystal production capability: 700 – 7,000 X-ray quality crystals (1-2.5 Å) generated per month for each program

Cocrystal Technology Platform –
Proven track record for broad spectrum antiviral leads



Cocrystal platform technology focuses on:

- Well validated drug targets
- Broad spectrum activity
- Drug resistance
- High potency

Robust Development Pipeline

Program		Discovery	Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3	Partner
Hepatitis C (HCV)	**CC-31244 – University of MD** (Pan-genotypic NS5B NNI)							
	CC-31244 - Hong Kong (Pan-genotypic NS5B NNI)							
Influenza	**CC-42344** (Influenza A PB2 inhibitor)							
	Influenza A/B inhibitor							MERCK
Norovirus	**Noro Polymerase Inhibitor**							

Cocrystal's HCV Strategy:
Shorter Duration Novel Combination Therapy

Multiple opportunities in developing shorter combination therapy with approved HCV drugs

Gilead EPCLUSA + CC-31244

AbbVie Mavyret + CC-31244

Other approved HCV drugs + CC-31244

Cocrystal's Next Wave Combination Therapy: CC-31244 Properties

- Potential best-in-class HCV NNI with a strong profile
  - Broad spectrum, potent NS5B polymerase inhibitor
  - High barrier to drug resistance
  - Effective against known NNI drug resistant variants
  - Liver targeting
  - Novel mechanism of action

CC-31244: Broad Spectrum HCV NNI

Demonstration of Cocrystal's Enabling Technology

HCV GT1 – GT6 NS5B polymerase crystals





Proven track record for broad spectrum antiviral leads

Hepatitis C Treatment Market Share



AbbVie's Mavyret Demonstrated a Shorter Treatment: From 12 Weeks To 8 Weeks

Approved broad spectrum HCV combination therapy

Nucleoside/NS5A inhibitors

Gilead's EPCLUSA
(sofosbuvir 400mg/ velpatasvir 100 mg)
12-week treatment
Approved June 2016

Protease/NS5A inhibitors

AbbVie's Mavyret
(glecaprevir 100 mg/ pibrentasvir 40 mg)
8-week treatment
Approved August 2017

CC-31244 Phase 1b Data - Superior Viral Load Reduction

- HCV RNA viral load decline of 3 logs by 48 hours (HCV GT1 subjects, N=14)
- After the NNI treatment, the viral load levels slowly increased



Best-in-Class Potential of Any NNI

Drug	Genotype	Dose (mg)	Treatment frequency	Viral load reduction (Log_{10}IU/ml)
CC-31244 ⬅	**Genotypes 1-6** ⬅	**400** ⬅	**QD** ⬅	**-3.0** ⬅
ABT-333* (Dasabuvir)	Genotype 1	400	BID	-1.08
		800	BID	-0.95
GS-9190 (Tegobuvir)	Genotype 1	40	BID	-1.0
		120	BID	-1.5

(* : approved DAA)

CC-31244 Phase 2a Study Design

Interim Topline Results Expected January 2019

Open-label, Phase 2a study evaluating the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV DAAs

- **Endpoints**
  - Efficacy: changes in HCV RNA viral load
  - Safety: adverse events (AEs) and laboratory abnormalities

Upcoming CC-31244 Phase 2a Study in Hong Kong

Sponsored and Conducted by the Humanity & Health Research Centre (Principle Investigator: Dr. George Lau)

Open-label, safety, tolerability and preliminary efficacy of CC-31244 in combination with Sofosbuvir and Daclatasvir with or without a protease inhibitor, for the treatment of HCV

- **Endpoints**
  - Safety: adverse events (AEs) and laboratory abnormalities
  - Preliminary Efficacy: changes in HCV RNA viral load

HCV Summary and Next Steps

- Showed an acceptable safety profile in both healthy volunteers and GT1 patients up to 400 mg x 7 days
- No serious adverse events or discontinuations due to adverse events
- Demonstrated HCV RNA viral load reduction of ~ 3 logs by 48 hours
- Demonstrated a sustained post-treatment antiviral effect after 7-day treatment
- Potential to be an important DAA in shorter duration HCV combination regimens
- Ongoing Phase 2a study with interim topline results expected January 2019
- Upcoming Phase 2a study in Hong Kong

Noro Virus Polymerase Inhibitor

Noro virus and Norwalk polymerase crystals



- No approved Noro antiviral drugs
- Potent and broad spectrum anti-Noro polymerase inhibitors
- First-in-class NNI
- Structure-based lead discovery ongoing

Cocrystal-HitGen-InterX Collaboration: Aimed at Rapid Lead Discovery Process

- Combines synergistic drug discovery platforms
- Breakthrough hit-to-lead process
- High quality novel leads will be developed

Financial Snapshot – Nasdaq: COCP

~$108MM
Market cap[1]

29.9MM
Common shares outstanding

~42K
Average daily volume[2]

1: Based on December 31, 2018 closing price of $3.60 per share
2: Based on December 31, 2018 Yahoo Finance

COCP Capitalization Table

Capitalization Table (As of December 31, 2018)	# of Shares	WAEP	$ Value	% of Fully Diluted
Common Shares Outstanding (Directors & Officers)	15,219,800			48.37%
Common Shares Outstanding (Other)	14,703,276			46.73%
Warrants	243,375	$10.28	$2,501,895	0.77%
Stock Options	1,297,953	$5.77	$7,483,658	4.13%
Fully Diluted Shares Outstanding	**31,464,404**			**100%**

Near-Term Milestones Expected to Drive Value

- Continue influenza A/B lead discovery (Merck collaboration)
- Continue preclinical studies of influenza A lead CC-42344
- Complete HCV CC-31244 Phase 2a (University of Maryland, Baltimore)
- Commence HCV CC-31244 Phase 2a (Humanity & Health Research Centre, Hong Kong)
- Continue Noro lead discovery


COCRYSTAL
PHARMA, INC.
Thank You!
NASDAQ: COCP
www.cocrystalpharma.com